Table 3 Preclinical studies targeting Tim-3
From: Tim-3 expression and its role in hepatocellular carcinoma
| Â | Anti-Tim-3 agents | Combining agents | Mechanism of combining agents | Diseases |
|---|---|---|---|---|
Anti-Tim-3 monotherapy | RMT3-23 | – | – | Sarcoma, colon adenocarcinoma, fibrosarcoma [71] |
5D12 | – | – | Lymphoma [72] | |
Tim-3Apt | – | – | ||
Combination of anti-Tim-3 agents with other agents | RMT3–23 | Anti-PD-1 antibody (clone: 29F.1A12) | Anti-PD-1 | Lung cancer [66] |
RMT3–23 | RMP1-14 | Anti-PD-1 | Melanoma, colon carcinoma [66] | |
RMT3–23 | UC10-4F10 | Anti-CTLA-4 | Melanoma [66] | |
RMT3–23 | RMP1-14 and UC10-4F10 | Anti-PD-1 and anti-CTLA-4 | Melanoma [66] | |
mTim-3 hFc | Anti-PD-1 antibody (clone: MIH7) | Anti-PD-1 | Acute myelogenous leukemia (AML) [67] | |
Anti-TIM-3 antibody (clone: 8B.2C12) | cc1 | Anti-CEACAM1 | Colorectal cancer [13] | |
RMT3–23 | Therapeutic anti-CD137 (clone: lob12.3) | Agonistic anti-CD137 antibody | Ovarian cancer [74] | |
Tim-3Apt | RMP1-14 | Anti-PD-1 | Colon carcinoma [77] | |
Tim-3Apt | Anti-PDL1 antibody (clone: 10F.9G2) | Anti-PDL1 | Colon carcinoma [78] | |
Combination of anti-Tim-3 agents with SRS | RMT3-23 | SRS | Radiotherapy | Glioma [73] |
RMT3-23 | Anti-PD-1 antibody, SRS | Anti-PD-1, radiotherapy | Glioma [73] |